OST OST
Company Profile ↓Company Overview
OST (OST) is a publicly traded company listed on with a market capitalization of $10.14M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Sep 2025 Revenue of $39.68M (+22.2% YoY); net profit $-10.02M.
- Trailing 12 Months Year-on-year growth — revenue +22.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -27.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -27.80% |
| 1 Year: | 22.23% |
Stock Price Performance
| 1 Year: | -4.24% |
| 6 Months: | +0.00% |
| 3 Months: | +0.00% |
| 1 Month: | +0.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)28.52 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -27.8% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 105.42M | 57.53M | 32.46M | 39.68M |
| Cost of Revenue | - | 92.80M | 55.47M | 30.78M | 37.14M |
| Gross Profit | - | 12.61M | 2.05M | 1.69M | 2.54M |
| Operating Expenses | - | 11.45M | 11.73M | 10.67M | 11.66M |
| Operating Income | - | 1.16M | -9.68M | -8.98M | -9.12M |
| EBITDA | - | 3.82M | -6.47M | -4.20M | -5.73M |
| Interest Expense | 1.11M | - | - | - | - |
| Pretax Income | - | 439.17K | -10.79M | -10.17M | -10.30M |
| Tax Provision | - | 326.94K | 227.32K | 23.15K | 15.59K |
| Net Income | - | 198.98K | -10.95M | -10.06M | -10.02M |
| Diluted EPS | - | 4.25 | -196.59 | -168.50 | -109.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 57.23M | 56.55M | 51.07M | 53.25M |
| Current Assets | - | 31.91M | 24.44M | 20.84M | 18.37M |
| Cash & Equivalents | - | 3.66M | 854.52K | 1.02M | 5.07M |
| Inventory | - | 15.43M | 14.42M | 11.11M | 6.35M |
| Receivables | - | 6.27M | 6.48M | 3.92M | 3.52M |
| Total Liabilities | - | 31.61M | 42.46M | 43.19M | 42.29M |
| Current Liabilities | - | 31.56M | 40.53M | 40.96M | 39.74M |
| Long Term Debt | 194.02K | - | 1.64M | 1.71M | 2.39M |
| Total Debt | - | 21.28M | 25.68M | 27.88M | 25.64M |
| Total Equity | - | 25.34M | 13.96M | 5.19M | 7.00M |
| Shares Outstanding | - | 56.02K | 56.02K | 65.96K | 5.96M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 9.70M | -2.59M | -4.94M | 85.25K |
| Investing Cash Flow | - | -6.88M | -6.99M | -1.39M | -7.29M |
| Financing Cash Flow | - | 11.79K | 7.72M | 6.75M | 10.95M |
| Capital Expenditure | - | -8.18M | -7.50M | -2.44M | -7.50M |
| Free Cash Flow | - | 1.52M | -10.09M | -7.38M | -7.42M |
| Net Change in Cash | - | 2.83M | -1.86M | 411.74K | 3.74M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 12.0% | 3.6% | 5.2% | 6.4% |
| Operating Margin % | - | 1.1% | -16.8% | -27.7% | -23.0% |
| Net Margin % | - | 0.2% | -19.0% | -31.0% | -25.2% |
| ROE % | - | 0.8% | -78.4% | -193.8% | -143.1% |
| ROCE % | - | 4.5% | -60.4% | -88.8% | -67.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OST
Ostin Technology Group Co., Ltd. Revenue Breakdown – NASDAQ:OST - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE1wcllqWEl6eDBZRTFNblhWdHFCMjYwZ3cydFZrV05GSktobTFIWG8za0c2dl90eHVmOTBucUw0QXlHR1dUa0VSdFBEcWVkQjgzMG1FeEw4RmxjeWJuMUJ3dVJ4NUNfc3NYRUx1RllSNGZ2VkhSc0E?oc=5" target="_blank">Ostin Te…
6 Best Music Stocks to Buy in 2026 - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNdWlDcGpDUWVNbEtBYjJCZFVQXzJKVVRLUm1uT1dMUllnUWI0bXdub094bTRsTEV5bDl1Z1NZWXA1ZmFxemVmcHhTZ1dHZWI5TFA5eVFLVTZoVTFwM2FReVVvOWhtc28wWUgyaTVVODlZdVJITzNBVkRsVmRzeGhqZ2wtaVVHelNCMk5HZm…
OST Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMiwgJBVV95cUxQSkd2d2l5SjJBTmtHNzJKVnU4aklNSEhsRE80NUU2a3VsaGJIUWRqTlJtY0tnY19kZmQ0eHVzR2p5VllJVndBUmxSR0FqMTdFRC0wTTRmSV9MaHZRVWhvY0pBTTh5Nlc1eU0yOUh5Q1BUZlNPWXNWdE9hcjI5MHVEUjZJRmJ2R3QxdEo0Z0…
OST'S $0.06 SHARES SOLD AS $9.40 WINNERS -- INVESTORS LOST 94%: LEVI & KORSINSKY, LLP - PR Newswire
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPaGVZUkZKbFlTZmlIM0oxVjMwMlRBcmljWFdwS2pzNnUzMGFUMHM0bnZ4ZlA4R2UxRmhDTEx0UlJpYWJaY09VdGZFNllVZXpxWDJKQTEwejF3Vlc2LXZadXU3WkhoRzlWeFZCeTlFdFRubUtOZ3pCVmxIemg5UTJkeFB1YmhqSDd0Zk5JTE…
Ostin Technology Group Co Ltd (OST) Income Statement - TradingKey
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE83OEg2dm5zeHNxQm4xVFg1cm5uYWxZekI4QjZGbURUVnVrY2loYlJPLVY3VnVHWGVWMFlzSVV2WnlBODhSNXJqaVQ1azAxQ2lYdFFidGlPdmphdTI4cDFsQUt6aDdXQUNJZFhWbUZRdw?oc=5" target="_blank">Ostin Technology …
OST-HER2 osteosarcoma immunotherapy seeks FDA accelerated approval, ASCO data due - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQODVJNjI1NzJiWk1haUQ3SmRuanQ3WTF4Q1RNcy1vckRFN1pDeWJWRm9KLWVnd0xKaWpJNmRvUWltUTlzZ0FzenVMdWk4YXVzOWJZVXJicmVtTS1hLUIyRGtjQ2dmZFFrY1pwcTQ5WmM0dmRrNExRdGhNajgxdDBiZ0ExRXRVa2ZDRG5OQz…
OST — Frequently Asked Questions
What is the current share price of OST?
As of 2026-08-05 17:25 PDT, OST trades at $1.70 on NASDAQ/NYSE. Its 52-week range is $1.46 to $2.25.
What is the market capitalisation of OST?
OST has a market capitalisation of $10.14M on NASDAQ/NYSE.
What is the P/E ratio of OST?
OST trades at a trailing price-to-earnings (P/E) ratio of -0.02. Its price-to-book (P/B) ratio is 1.45.
What is the return on equity (ROE) of OST?
OST has a return on equity (ROE) of -143.09%. Its return on capital employed (ROCE) is -67.47%.
Is OST a good stock to buy?
This page provides a data-driven analysis of OST, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.